CN109363164A - 一种能改善微循环的含小分子肽的口服液及其制备方法 - Google Patents
一种能改善微循环的含小分子肽的口服液及其制备方法 Download PDFInfo
- Publication number
- CN109363164A CN109363164A CN201811401299.6A CN201811401299A CN109363164A CN 109363164 A CN109363164 A CN 109363164A CN 201811401299 A CN201811401299 A CN 201811401299A CN 109363164 A CN109363164 A CN 109363164A
- Authority
- CN
- China
- Prior art keywords
- parts
- microcirculation
- people
- oral solution
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
- 230000004089 microcirculation Effects 0.000 title claims abstract description 50
- 229940100688 oral solution Drugs 0.000 title claims abstract description 43
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 24
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 15
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 15
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 15
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 12
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 11
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 10
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims abstract description 8
- 244000068988 Glycine max Species 0.000 claims abstract description 8
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 8
- 235000021307 Triticum Nutrition 0.000 claims abstract description 8
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims abstract description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 7
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 244000179886 Moringa oleifera Species 0.000 claims abstract 3
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 3
- 241000209140 Triticum Species 0.000 claims description 7
- 239000001556 apium graveolens l. seed extract Substances 0.000 claims description 7
- 229940116732 celery seed extract Drugs 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 6
- 240000002045 Guettarda speciosa Species 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- 235000013793 astaxanthin Nutrition 0.000 claims description 6
- 239000001168 astaxanthin Substances 0.000 claims description 6
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 6
- 229940022405 astaxanthin Drugs 0.000 claims description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 6
- 235000011086 calcium lactate Nutrition 0.000 claims description 6
- 239000001527 calcium lactate Substances 0.000 claims description 6
- 229960002401 calcium lactate Drugs 0.000 claims description 6
- 235000005471 carotenols Nutrition 0.000 claims description 6
- 150000001748 carotenols Chemical class 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 229940013618 stevioside Drugs 0.000 claims description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- 239000008280 blood Substances 0.000 abstract description 29
- 210000004369 blood Anatomy 0.000 abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 24
- 150000002632 lipids Chemical class 0.000 abstract description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 14
- 230000006872 improvement Effects 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000002929 anti-fatigue Effects 0.000 abstract description 3
- 210000000748 cardiovascular system Anatomy 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract description 3
- 210000000653 nervous system Anatomy 0.000 abstract description 3
- 230000003860 sleep quality Effects 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 abstract description 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 102000005606 Activins Human genes 0.000 abstract 1
- 108010059616 Activins Proteins 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000098338 Triticum aestivum Species 0.000 abstract 1
- 239000000488 activin Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 34
- 208000035475 disorder Diseases 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 241000220215 Moringa Species 0.000 description 12
- 241000208340 Araliaceae Species 0.000 description 9
- 241000229143 Hippophae Species 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241001669679 Eleotris Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010072661 Angiotensin Amide Proteins 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000189115 Catananche Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- -1 n-butene acyl lactone Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种能改善微循环的含小分子肽的口服液及其制备方法,所述口服液将大豆低聚肽、小麦低聚肽、人参肽和骨胶原蛋白肽粉与辣木酵素、荷叶提取物、当归提取物、沙棘果提取物以及其它辅料有机地结合在一起,通过科学合理搭配促进小分子肽在人体内更好地吸收从而快速发挥其功效。本发明所提供的口服液能在最短的时间内有效增加人体循环动力,激活人体细胞、软化疏通全身血管,活化周身神经,改善微循环,清除体内毒素,辅助人们恢复正常新陈代谢,从而有效改善人体的微循环,例如:它能降低甘油三酯和胆固醇等血脂主要成分的浓度,从而改善心血管系统微循环障碍;它还能提高免疫力、抗疲劳和改善睡眠质量,从而改善神经系统微循环障碍。
Description
技术领域
本发明涉及营养口服液,具体涉及一种能改善微循环的含小分子肽的口服液及其制备方法。
背景技术
微循环是指人体微动脉和微静脉之间的血液循环,它最根本的功能是进行血液和组织之间的物质交换。人体每个器官和每个组织细胞均要由微循环提供氧气、养料、传递能量、交流信息、排除二氧化碳及代谢废物等。
现代医学研究已证明:人体的衰老、肿瘤的发生、高血压、糖尿病及许多心脑血管等疾病,主要是微循环障碍所致,因此,微循环正常与否是衡量人体健康的重要标志之一。然而,现今人们的生活方式中的各种不良饮食习惯、超重的工作压力及环境污染等都会让各种杂质(例如:胆固醇、酒精、尼古丁、药物残渣和化学残留物等)混浊在人体血液中使血管壁变厚,有时还会堵塞血管,造成血液运行不畅导致微循环障碍,这是导致微循环障碍的最主要外部原因。另一方面,随着年龄的增长,人体的细胞和血液会逐渐衰老,功能也自然随之退化,这是造成微循环障碍内部原因。
人体一旦发生微循环障碍,轻则处于亚健康状态,重则百病从生,例如:脑部发生微循环障碍会造成供血不足,脑细胞得不到充足的氧气和养料,代谢产物不能充分顺利排除,而导致头晕、头痛、失眠、多梦、记忆力下降、神经衰弱、重者会发生脑梗塞、中风等症;心脏发生微循环障碍,引起心肌供血不足,产生胸闷、心慌、心律不齐、心绞痛等冠心病的症状,甚至发生心肌梗死;肺发生微循环障碍时,则会发生胸闷、气短、咳嗽、哮喘、支气管炎等;胃发生微循环障碍,就会引起胃的功能紊乱,营养吸收不良,发生胃炎、溃疡病以及其他胃部病变。内分泌系统发生微循环障碍时,可导致各种激素分泌紊乱,引发甲关腺功能亢进、糖尿病、乳腺炎和小叶增生等;泌尿生殖系统发生微循环障碍时,导致肾炎、肾衰、女性盆腔炎、月经不调、男性前列腺炎、膀胱炎等。
目前虽然可通过一些扩张血管的药物来改善症状,但药物治疗存在一定风险,且只能缓解症状,不能从根本上解决问题。市面上还缺少通过食疗来改善微循环的天然营养品,小分子肽是分子结构介于氨基酸和蛋白质之间的一类化合物,它具有调节机体生理功能和为机体提供营养的双重功效,它几乎影响着人体的一切代谢合成。研究表明:小分子肽具有调节神经系统、活化细胞免疫机能、改善心血管功能和抗衰老等生理活性,这为开发肽药物、肽类保健食品提供了理论依据。因此,利用各种小分子肽与其它天然物质结合来开发具有改善微循环的口服液是非常有意义的。
发明内容
为了达成上述目的,本发明的解决方案是:
一种能改善微循环的含小分子肽的口服液,其特征在于,所述改善微循环的口服液的原料含量按重量份数计算如下:胶原蛋白1-3份,骨胶原蛋白肽粉3-5份,虾青素0.1-0.2份,大豆低聚肽3-6份,小麦低聚肽3-6份,低聚麦芽糖1-2份,乳酸钙0.5-1份,人参肽1-2份,辣木酵素1-3份,西芹籽提取物0.1-0.2份,天然叶黄素0.1-0.2份,沙棘果提取物4-6份,荷叶提取物2-3份,黄精提取物1-2份,当归提取物1-2份,甜菊糖1-3份,纯净水为90-110份。
优选地,所述胶原蛋白为深海鱼皮胶原蛋白。
一种能改善微循环的含小分子肽的口服液的制备方法,其特征在于,具体包括如下步骤:
(1)将胶原蛋白、骨胶原蛋白肽粉、大豆低聚肽、小麦低聚肽和人参肽加入到水中加热至80℃搅拌均匀,冷却至室温制得多肽溶液;
(2)往步骤(1)中制备的蛋白多肽溶液加入虾青素、低聚麦芽糖、乳酸钙、辣木酵素、西芹籽提取物、天然叶黄素、荷叶提取物、黄精提取物、当归提取物、沙棘果提取物和甜菊糖,所得混合物搅拌均匀再经灌装和灭菌后即得制得所述能改善微循环的含小分子肽的口服液。
下面对本发明中所使用的主要活性原料和辅料作详细介绍:
胶原蛋白是修复人体受损组织的重要原料物质。当人体真皮层的胶原蛋白被氧化断裂后,对表皮的支撑作用就消失了,因此造成不均一的塌陷,这样皱纹就产生了,而补充胶原蛋白能使肌肤变得细腻和润滑,细小皱纹能得到很好的舒展,肤色有所增白。
骨胶原蛋白肽粉是从牛羊等动物皮肤或骨骼中提取分离得来的天然生物活性小分子肽,具有抑制血管紧张素转化酶活性、抑制血小板凝结活性、抗氧化活性及抗肿瘤活性等。
虾青素具有多种生理功效,如在抗氧化性、抗肿瘤、预防癌症、增强免疫力和改善视力等方面都有一定的效果。
大豆低聚肽是大豆的水解产物,其氨基酸组成与大豆蛋白一样,除具有优质蛋白的特点以外,还具有大豆蛋白所不具备的良好的溶解性、稳定性等理化性质,而且具有易吸收和低过敏原性、降低血脂和胆固醇、降低血压、促进矿物质吸收和脂肪代谢及增强体能等多种生理功能。
小麦低聚肽是小麦蛋白粉水解后分离获得的小分子多肽物质,在保持原蛋白营养特性的同时,还具有良好的水溶性、乳化性和配伍性,并且含有丰富的谷氨酰胺;而谷氨酰胺是维持脑氨平衡和作为神经递质的前体物质。
乳酸钙是一种补钙剂,具有促进骨骼及牙齿的钙化形成、维持神经与肌肉的正常兴奋性和降低毛细血管通透性等作用。
低聚麦芽糖除了作为甜味剂之外,对人体内有益的双歧杆菌有强大的增殖作用,净化肠道,促进肠蠕动,防止和解除便秘及腹泻,抑制体内有害菌的繁殖和有毒腐败物质的产生。对分泌体内多种毒素的产气荚膜梭状芽胞杆菌有明显抑制作用,增强免疫力、降低胆固醇和血脂,促进老年人对钙质的吸收,是驻防老年人骨质疏松的有效营养补剂,还可阻断蔗糖被变异链球菌分解,抑制蛀牙。
人参肽是从人参或人参蛋白质水解产物中获取的具有生物活性功能的小分子肽,具有提高免疫力、抗氧化、抗疲劳、提高或改善性功能、降血糖、降血脂、提高缺氧耐受力、增强抗辐照能力、保肝护肝、清咽等作用;完整保留了人参的营养价值和活性成分,又克服了传统人参服用方法繁琐、难吸收、易上火及不易储存等弊端。
辣木酵素富含多酚及其苷类、总黄酮类、辣木活性多糖,辣木树素、生物碱等数十种对人健康有效成份,它对排除人体健康威胁最大的血糖毒素和血脂毒素并逐步治愈糖尿病和改善“三高”人群亚健康有极大促进作用,清除血液糖毒、脂肪毒素、净化血液的效果,对于高血糖、血管硬化有良好的调治作用。
荷叶提取物中含有荷叶碱、荷叶黄酮、柠檬酸及烟酸等物质,具有利尿通便、通肠毒、降脂除油、清暑解热等作用,能明显降低血清中甘油三醇和胆固醇含量,具有调节血脂的保健作用。
黄精是中医传统补中益气药,属药食两用中药,服用安全。黄精多被用于治疗脾胃虚弱、阴虚肺燥、干咳少痰、须发早白、精血不足、内热消渴等症。现代医学研究表明,黄精提取物具有降血压、降血糖、降血脂、防止动脉粥样硬化、延缓衰老和抗菌的作用,对于糖尿病也很有疗效,对多种细菌和皮肤真菌有抑制作用。
当归提取物中含有藁本内酯、正丁烯酰内酯及阿魏酸等物质,具有养血和血,补血调经,活血止痛和润肠通便等功效。
沙棘果提取物中含有香豆素,能够增强毛细血管功能,可以解痉、抗白癜风、麻醉、解热和利胆等;沙棘黄酮及其它活性物质具有降低高血压、软化血管,改善血液循环等作用,对缺血性脑血管病有防治和缓解作用,具有改善大脑供血供氧等作用。另外,沙棘果提取物中所含有的白花青素、苦木素和5-羟色胺等成分还可以抗肿瘤,可以直接抑制癌细胞作用以及阻断致癌因素的作用。
西芹籽提取物中所含降压和降脂成分是芹菜的50倍,短期服用即可起到降血压,降血脂的作用,长期饮用能使血压平稳,清火、镇静和解暑。
天然叶黄素是一种优良的抗氧化剂,能抵御游离基在人体内造成细胞与器官损伤,从而可防止机体衰老引发的心血管硬化、冠心病和肿瘤病等。叶黄素是眼睛中仅有的2种类胡萝卜素之一,具有预防老年性眼球视网膜黄斑区病变引起的视力下降与失明是叶黄素的独特功能。
甜菊糖是一种从菊科草本植物甜叶菊中精提的天然甜味剂。它具有高甜度和低热量的特点,其甜度是蔗糖的200-300倍,热量仅为蔗糖的1/300。经大量药物实验证明,甜菊糖食用安全,是一种可替代蔗糖的甜味剂。国外食品专家及医学专家临床实验证实,该产品对糖糖尿病、高血压有一定的疗效,对肥胖病、心血管疾病、胃炎、口腔疾病及胃酸过多等亦有一定的辅助治疗作用。。
本发明的原理及增益效果如下:
(1)本发明提供了一种能快速改善微循环功能的含小分子肽的口服液,通过科学的选材和合理的搭配:将植物来源的天然小分子肽(大豆低聚肽、小麦低聚肽和人参肽)和动物来源的天然小分子肽(骨胶原蛋白肽粉)与辣木酵素、西芹籽提取物、天然抗氧化剂以及其它辅料有机地结合在一起,与含单一小分子肽或单独使用辣木酵素的营养品不同,这样的互补搭配能促进小分子肽和辣木酵素在人体内更好地吸收从而快速发挥其功效。本发明所提供的快速改善微循环的口服液能在最短的时间内直接有效增加人体循环动力,激活人体细胞、软化疏通全身血管,活化周身神经,改善微循环,清除体内毒素,辅助人们恢复正常新陈代谢,从而有效改善人体的微循环,例如:它能降低甘油三酯和胆固醇等血脂主要成分的浓度,从而改善心血管系统微循环障碍,从而可治疗和预防与高脂血症相关联的病症;它还能提高免疫力、抗疲劳和改善睡眠质量,从而改善神经系统微循环障碍;此外,它还能抗氧化,促进新陈代谢和细胞修复,提高人体肌肤光滑细腻,进而达到抗衰老效果。
(2)本发明所提供的能快速改善微循环功能的含小分子肽的口服液的主要活性分均来自天然食材,辅料均为食品行业常用原料,长期服用无任何毒害作用。
(3)本发明所提供的能快速改善微循环功能的含小分子肽的口服液还具有色泽均匀,澄清度高,质量稳定性好,香味浓郁及口感细腻等优点。本发明所提供的口服液制备方法简单,适于产业化应用。
具体实施方式
下面进一步结合实施例以详细说明本发明。同样应理解,以下实施例只用于对本发明进行进一步说明,不能理解为对本发明保护范围的限制,示例中具体的质量、反应时间和温度、工艺参数等也仅是合适范围中的一个示例,本领域的技术人员根据本发明的上述内容做出的一些非本质的改进和调整均属于本发明的保护范围。
实施例1-3和对比例1-3
按照表1的配料比例制备能快速改善微循环的口服液:
表1
实施例1-3和对比例1-3的制备的所有操作均在洁净区内进行,具体步骤如下:
(1)按重量称取胶原蛋白(此处为深海鱼皮胶原蛋白)、骨胶原蛋白肽粉、大豆低聚肽、小麦低聚肽和人参肽,然后加入到水中加热至80℃搅拌均匀,冷却至室温制得多肽溶液;
(2)按重量往步骤(1)中制备的蛋白多肽溶液加入虾青素、低聚麦芽糖、乳酸钙、辣木酵素、西芹籽提取物、天然叶黄素、荷叶提取物、黄精提取物、当归提取物、沙棘果提取物和甜菊糖,所得混合物搅拌均匀再经灌装和灭菌后即得制得所述能改善微循环的含小分子肽的口服液。
本发明所制备能快速改善微循环功能的含小分子肽的口服液的使用方法如下:
每日早晚餐前取口服液25毫升服用。
本发明所制备能快速改善微循环功能的含小分子肽的口服液的效果测试如下:
案例1改善心血管微循环测试:
与20家医疗机构合作,选取120名40~60岁年龄层存在高血脂的人士分为4个组(编号分别为甲组,乙组、丙和丁组)每组30人(男女各15人)进行试用,其中甲组服用实施例2制备的口服液,乙组服用对比例1制备的口服液,丙组服用对比例2制备的口服液,丁组服用对比例3制备的口服液,每天早晚各一次,5日为一个疗程,服用5日后进行血脂测试,将所收集的调查表数据整理获得使用效果统计数据见表2-表5,其中,血脂下降率大于40%的记为效果显著,血脂下降率高于5%低于40%的记为效果一般,血脂下降率低于5%的记为无效。
表2服用口服液5日降血脂统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 19人 | 9人 | 2人 |
对比例1 | 0人 | 2人 | 28人 |
对比例2 | 6人 | 11人 | 13人 |
对比例3 | 5人 | 14人 | 11人 |
表3服用口服液10日降血脂统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 24人 | 5人 | 1人 |
对比例1 | 0人 | 3人 | 27人 |
对比例2 | 9人 | 12人 | 9人 |
对比例3 | 8人 | 12人 | 10人 |
表4服用口服液15日降血脂统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 28人 | 1人 | 1人 |
对比例1 | 0人 | 3人 | 27人 |
对比例2 | 10人 | 13人 | 7人 |
对比例3 | 11人 | 11人 | 8人 |
表5服用口服液30日降血脂统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 29人 | 0人 | 1人 |
对比例1 | 0人 | 2人 | 28人 |
对比例2 | 14人 | 11人 | 5人 |
对比例3 | 13人 | 10人 | 7人 |
由表2-表5可以看出实施例2为本发明所提供的快速改善微循环的口服液的优选方案,它将4种小分子肽、辣木酵素和沙棘果提取物结合在一起,可以快速清除人体心血管内的沉积的甘油三脂和胆固醇等垃圾,降血脂效果非常显著;对比例1中没有添加任何小分子肽,结果表明它基本没有降血脂效果;对比例2中没有添加辣木酵素,结果表明服用后降血脂速度较慢,效果一般;对比例3中没有添加沙棘果提取物,结果表明其降血脂速度慢,效果也一般。服用实施例2制备的口服液30日后降血脂的效果显著率可超过96%,由此可以看出往小分子肽中添加辣木酵素和沙棘果提取物能有助于人体对小分子肽的吸收,可降低甘油三酯和胆固醇等血脂主要成分的浓度,从而改善心血管系统微循环障碍,从而可治疗和预防与高脂血症相关联的病症。
案例2改善睡眠测试:
与10家理疗院合作,选取200名35~50岁年龄层失眠人士分为4个组(编号分别为甲组,乙组、丙和丁组)每组50人(男女各25人)进行试用,其中甲组服用实施例2制备的口服液,乙组服用对比例1制备的口服液,丙组服用对比例2制备的口服液,丁组服用对比例3制备的口服液,每天早晚各一次,5日为一个疗程,每天收集分发给使用者的智能手环睡眠数据,将所收集的调查表数据整理获得使用效果统计数据见表6-表9,其中睡眠时间与服用前相比延长超过40%的记为效果显著,睡眠延长时间超过10%低于40%的记为效果一般,延长时间低于10%的记为无效。
表6服用口服液1日后改善睡眠效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 27人 | 13人 | 10人 |
对比例1 | 0人 | 3人 | 47人 |
对比例2 | 7人 | 10人 | 33人 |
对比例3 | 5人 | 11人 | 34人 |
表7服用口服液5日后改善睡眠效果统计数据
表8服用口服液10日后改善睡眠效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 45人 | 3人 | 2人 |
对比例1 | 0人 | 9人 | 41人 |
对比例2 | 14人 | 25人 | 11人 |
对比例3 | 13人 | 28人 | 9人 |
表9服用口服液15日后改善睡眠效果统计数据
效果显著 | 效果一般 | 无效 | |
实施例2 | 49人 | 1人 | 0人 |
对比例1 | 0人 | 10人 | 40人 |
对比例2 | 26人 | 15人 | 9人 |
对比例3 | 28人 | 14人 | 8人 |
由表6-表9可以看出超过50%的人服用本发明所提供的快速改善微循环的口服液一日后睡眠就有了显著的改善,服用15日后对睡眠效果的显著改善率为100%;而服用对比例1的口服液后对睡眠效果基本没有改善作用,服用对比例2和对比例3的口服液后对睡眠的改善速度慢,效果也一般。由此可以看出往小分子肽中添加辣木酵素和沙棘果提取物能有助于人体对小分子肽的吸收,从而有助于快速改善人体神经系统微循环,有效改善睡眠质量。
Claims (3)
1.一种能改善微循环的含小分子肽的口服液,其特征在于,所述改善微循环的口服液的原料含量按重量份数计算如下:胶原蛋白1-3份,骨胶原蛋白肽粉3-5份,虾青素0.1-0.2份,大豆低聚肽3-6份,小麦低聚肽3-6份,低聚麦芽糖1-2份,乳酸钙0.5-1份,人参肽1-2份,辣木酵素1-3份,西芹籽提取物0.1-0.2份,天然叶黄素0.1-0.2份,沙棘果提取物4-6份,荷叶提取物2-3份,黄精提取物1-2份,当归提取物1-2份,甜菊糖1-3份,纯净水为90-110份。
2.根据权利要求1所述的能改善微循环的含小分子肽的口服液,其特征在于,所述胶原蛋白为深海鱼皮胶原蛋白。
3.一种根据权利要求1所述的能改善微循环的含小分子肽的口服液的制备方法,其特征在于,具体包括如下步骤:
(1)将胶原蛋白、骨胶原蛋白肽粉、大豆低聚肽、小麦低聚肽和人参肽加入到水中加热至80℃搅拌均匀,冷却至室温制得多肽溶液;
(2)往步骤(1)中制备的蛋白多肽溶液加入虾青素、低聚麦芽糖、乳酸钙、辣木酵素、西芹籽提取物、天然叶黄素、荷叶提取物、黄精提取物、当归提取物、沙棘果提取物和甜菊糖,所得混合物搅拌均匀再经灌装和灭菌后即得制得所述能改善微循环的含小分子肽的口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811401299.6A CN109363164A (zh) | 2018-11-22 | 2018-11-22 | 一种能改善微循环的含小分子肽的口服液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811401299.6A CN109363164A (zh) | 2018-11-22 | 2018-11-22 | 一种能改善微循环的含小分子肽的口服液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109363164A true CN109363164A (zh) | 2019-02-22 |
Family
ID=65377299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811401299.6A Pending CN109363164A (zh) | 2018-11-22 | 2018-11-22 | 一种能改善微循环的含小分子肽的口服液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109363164A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115005434A (zh) * | 2022-07-20 | 2022-09-06 | 完美(广东)日用品有限公司 | 一种用于改善微循环的组合物、液体制剂及其制备方法与应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04341167A (ja) * | 1991-05-14 | 1992-11-27 | Asahi Breweries Ltd | 大豆ペプチド入り人参発酵飲料 |
CN1742605A (zh) * | 2005-09-30 | 2006-03-08 | 北京康比特威创体育新技术发展有限公司 | 一种大豆肽饮料 |
CN103156255A (zh) * | 2013-02-04 | 2013-06-19 | 张清明 | 健心脑耳肽保健食品和饮品系列产品及其制作方法 |
CN103689732A (zh) * | 2013-10-14 | 2014-04-02 | 诺利如一(安阳)生物科技有限公司 | 一种大豆肽风味饮料 |
CN103689733A (zh) * | 2013-10-14 | 2014-04-02 | 诺利如一(安阳)生物科技有限公司 | 一种大豆肽风味饮料的制备方法 |
CN103845722A (zh) * | 2012-11-29 | 2014-06-11 | 江中药业股份有限公司 | 一种防治辐射损伤或化学药物治疗损伤的低聚肽组合物及其制备方法 |
CN104738784A (zh) * | 2015-04-10 | 2015-07-01 | 山东农业大学 | 一种天然复合植物源功能饮料 |
CN105942490A (zh) * | 2016-03-30 | 2016-09-21 | 北京森源华诚科技发展有限公司 | 一种防治高血脂高血糖高血压的复合酵素组合物 |
CN107259234A (zh) * | 2017-06-06 | 2017-10-20 | 北京知药医疗科技有限公司 | 一种无糖的胶原蛋白饮料 |
CN108308480A (zh) * | 2018-02-01 | 2018-07-24 | 杨茉莉 | 一种生物瘦身降高疏秘保健品及其制备方法 |
-
2018
- 2018-11-22 CN CN201811401299.6A patent/CN109363164A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04341167A (ja) * | 1991-05-14 | 1992-11-27 | Asahi Breweries Ltd | 大豆ペプチド入り人参発酵飲料 |
CN1742605A (zh) * | 2005-09-30 | 2006-03-08 | 北京康比特威创体育新技术发展有限公司 | 一种大豆肽饮料 |
CN103845722A (zh) * | 2012-11-29 | 2014-06-11 | 江中药业股份有限公司 | 一种防治辐射损伤或化学药物治疗损伤的低聚肽组合物及其制备方法 |
CN103156255A (zh) * | 2013-02-04 | 2013-06-19 | 张清明 | 健心脑耳肽保健食品和饮品系列产品及其制作方法 |
CN103689732A (zh) * | 2013-10-14 | 2014-04-02 | 诺利如一(安阳)生物科技有限公司 | 一种大豆肽风味饮料 |
CN103689733A (zh) * | 2013-10-14 | 2014-04-02 | 诺利如一(安阳)生物科技有限公司 | 一种大豆肽风味饮料的制备方法 |
CN104738784A (zh) * | 2015-04-10 | 2015-07-01 | 山东农业大学 | 一种天然复合植物源功能饮料 |
CN105942490A (zh) * | 2016-03-30 | 2016-09-21 | 北京森源华诚科技发展有限公司 | 一种防治高血脂高血糖高血压的复合酵素组合物 |
CN107259234A (zh) * | 2017-06-06 | 2017-10-20 | 北京知药医疗科技有限公司 | 一种无糖的胶原蛋白饮料 |
CN108308480A (zh) * | 2018-02-01 | 2018-07-24 | 杨茉莉 | 一种生物瘦身降高疏秘保健品及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115005434A (zh) * | 2022-07-20 | 2022-09-06 | 完美(广东)日用品有限公司 | 一种用于改善微循环的组合物、液体制剂及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106722963A (zh) | 一种素食餐 | |
CN101773595B (zh) | 清肝明目中药茶 | |
CN110354204B (zh) | 一种具有明目功效的组合物及其制备、应用方法 | |
CN105533688A (zh) | 一种辅助降血糖保健软胶囊及其制备方法 | |
CN106562428A (zh) | 一种美颜美体膏滋及其制备方法 | |
CN110037113A (zh) | 一种女士瘦身养颜奶粉 | |
CN105233100A (zh) | 一种治疗糖尿病的饮料及其制备方法 | |
CN105124605A (zh) | 一种保健咀嚼片及其制备方法 | |
US8715650B2 (en) | Bathing composition and method for preparing same | |
CN109259022A (zh) | 一种能快速改善微循环功能的含小分子肽的饮品 | |
CN106923130A (zh) | 含西红花的固体饮料、其制备方法及应用 | |
CN1900255A (zh) | 男性健美长寿液 | |
CN100574786C (zh) | 一种甲鱼制剂的生产工艺 | |
CN111713699A (zh) | 燕窝减肥组合物,其功能食品、制备方法及应用 | |
CN102511876B (zh) | 山楂红枣浓浆及其生产工艺 | |
CN107668569A (zh) | 一种延缓衰老的海参蜂王浆及其生产方法 | |
CN109820123A (zh) | 一种改善微循环的植物饮品及其制备方法 | |
CN109363164A (zh) | 一种能改善微循环的含小分子肽的口服液及其制备方法 | |
CN101991110B (zh) | 野生灵芝系列食品 | |
CN109730222A (zh) | 酵素复合液及其保健饮料 | |
CN116076710A (zh) | 一种具有抗衰美白功能的玫瑰本草酵素及其制备方法和应用 | |
KR20080090808A (ko) | 피부미용을 위한 건강보조식품의 조성물 | |
CN105331477A (zh) | 一种白葡萄酒及其制备方法 | |
CN105176773A (zh) | 一种调节血糖的南瓜酒及其制作方法 | |
CN109566826A (zh) | 一种抗衰老提高免疫力美容的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190222 |